AXSM - Axsome Therapeutics Inc. (AXSM) Q4 2023 Earnings Call Transcript
2024-02-20 18:47:07 ET
Axsome Therapeutics, Inc. (AXSM)
Q4 2023 Earnings Conference Call
February 20, 2024 08:00 AM ET
Company Participants
Mark Jacobson - Chief Operating Officer
Herriot Tabuteau - Chief Executive Officer
Nick Pizzie - Chief Financial Officer
Ari Maizel - Executive Vice President and Head of Commercial
Hunter Murdock - General Counsel
Conference Call Participants
Leonid Timashev - RBC Capital Markets
Charles Duncan - Cantor Fitzgerald
Ash Verma - UBS
Jason Gerberry - Bank of America
David Amsellem - Piper Sandler
Joseph Thome - TD Cowen
Marc Goodman - Leerink Partners
Graig Suvannavejh - Mizuho Securities
David Hoang - Citigroup
Myles Minter - William Blair
Eddie Hickman - Guggenheim Securities
Matthew Kaplan - Ladenburg Thalmann
Vikram Purohit - Morgan Stanley
Presentation
Operator
Hello and welcome to the Axsome Therapeutics Fourth Quarter and Full-Year 2023 Conference Call and Webcast. [Operator Instructions]. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Chief Operating Officer, Mark Jacobson. Please go ahead, sir.
Mark Jacobson
Good morning, and thank you all for joining us on today's conference call. This morning, we issued our earnings press release providing a corporate update and details of the company's financial results for the fourth quarter and full-year of 2023. The release crossed the wire a short time ago and is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct, and the source of future clinical trials, regulatory plans, future research and development plans, our commercial plans regarding Sunosi, Auvelity, and our pipeline products, revenue projections, and possible intended use of cash and investments.
These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today's date, and the company disclaims any obligation to update such statements....
Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript